Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model.
Renal artery stenosis (RAS) is an important cause of chronic renal dysfunction. Recent studies have underscored a critical role for CCL2 (MCP-1)-mediated inflammation in the progression of chronic renal damage in RAS and other chronic renal diseases. In vitro studies have implicated p38 MAPK as a critical intermediate for the production of CCL2. However, a potential role of p38 signaling in the development and progression of chronic renal disease in RAS has not been previously defined. We sought to test the hypothesis that inhibition of p38 MAPK ameliorates chronic renal injury in mice with RAS. We established a murine RAS model by placing a cuff on the right renal artery and treated mice with the p38 inhibitor SB203580 or vehicle for 2 wk. In mice treated with vehicle, the cuffed kidney developed interstitial fibrosis, tubular atrophy, and interstitial inflammation. In mice treated with SB203580, the RAS-induced renal atrophy was reduced (70% vs. 39%, P < 0.05). SB203580 also reduced interstitial inflammation and extracellular matrix deposition but had no effect on the development of hypertension. SB203580 partially blocked the induction of CCL2, CCL7 (MCP-3), CC chemokine receptor 2 (CCR2), and collagen 4 mRNA expression in the cuffed kidneys. In vitro, blockade of p38 hindered both TNF-α and TGF-β-induced CCL2 upregulation. Based on these observations, we conclude that p38 MAPK plays a critical role in the induction of CCL2/CCL7/CCR2 system and the development of interstitial inflammation in RAS.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Diping
D
Wang
Gina M
GM
Warner
Ping
P
Yin
Bruce E
BE
Knudsen
Jingfei
J
Cheng
Kim A
KA
Butters
Karen R
KR
Lien
Catherine E
CE
Gray
Vesna D
VD
Garovic
Lilach O
LO
Lerman
Stephen C
SC
Textor
Karl A
KA
Nath
Robert D
RD
Simari
Joseph P
JP
Grande
D000818:Animals; D001284:Atrophy / Q000473:pathology; D018932:Chemokine CCL2 / Q000096:biosynthesis*; D054410:Chemokine CCL7 / Q000096:biosynthesis; D004195:Disease Models, Animal; D005355:Fibrosis; D007093:Imidazoles / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009400:Nephrosclerosis / Q000473:pathology*; D011725:Pyridines / Q000494:pharmacology; D054390:Receptors, CCR2 / Q000096:biosynthesis; D012078:Renal Artery Obstruction / Q000473:pathology* / Q000517:prevention & control; D015398:Signal Transduction / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*
C491768:Ccl2 protein, mouse; C515451:Ccl7 protein, mouse; C515335:Ccr2 protein, mouse; D018932:Chemokine CCL2; D054410:Chemokine CCL7; D007093:Imidazoles; D011725:Pyridines; D054390:Receptors, CCR2; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580